Q2 2024 Atomo Diagnostics Ltd Activities Report Call Transcript
Hello, everyone, and welcome to the quarter 2 report from Atomo's FY '24 period. I'm John Kelly, the Managing Director of Atomo, and welcome this morning.
Before I jump into the quarterly, I just wanted to, I think, step back 12 months to the Q2 period for FY '23. At that stage, we had just come out of the COVID pandemic and Atomo, like a number of -- or most diagnostics companies, had seen a fairly abrupt end to COVID revenues. And there was a lot of uncertainty in the market around the future growth opportunities for diagnostics companies more broadly. And I think that uncertainty was reflected as well as the loss of COVID revenue was reflected in a lot of pressure on diagnostic companies share prices.
Atomo at that time said to shareholders that we were looking to refocus on our core business, which was essentially blood-based testing and that we knew 2 things. One, that our blood tests were best-in-class, and there would be a return to demand for them as our existing customers and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
